Jun 14, 04
|
| 17:47 ET |
OBiS(R) Announces Results from Survey at the 2004 Annual ASCO Conference in New Orleans
|
|
Jun 09, 04
|
| 19:13 ET |
Webcast Archive of Investor Meeting at ASCO Available on Cell Therapeutics, Inc. Website
|
|
| 08:32 ET |
VAMC and Agennix Release Lactoferrin Cancer Trial Results at ASCO
|
|
Jun 08, 04
|
| 16:21 ET |
Scientific Data Presented at ASCO Annual Meeting Demonstrating Synergy of QUADRAMET(TM) with Chemotherapy and Bisphosphonates
|
|
| 10:30 ET |
Scientific Data Presented at ASCO Annual Meeting Evaluating ERBITUX(TM) (Cetuximab) in Head and Neck Cancer (Abstracts 5502 and 5513)
|
|
| 10:15 ET |
Femara(R) is First Hormonal Therapy to Significantly Reduce Spread of Early Breast Cancer to Other Parts of the Body After Standard Tamoxifen Treatment in Postmenopausal Women
|
|
| 09:02 ET |
Genentech Presents Data From Broad Avastin Clinical Trial Program at the American Society of Clinical Oncology Meeting
|
|
| 07:02 ET |
American Pharmaceutical Partners Reports Tolerability of High Dose ABRAXANE(TM) Administered Weekly in Patients With Advanced Cancers
|
|
| 07:01 ET |
Polyglutamate Technology Enhances Tolerability of Important Class of Chemotherapy and Demonstrates Encouraging Anti-tumor Activity
|
|
| 00:01 ET |
Transgene Presents Data on MVA-MUC1-IL2 Cancer Vaccine at ASCO and ASGT Annual Meetings
|
|
Jun 07, 04
|
| 12:15 ET |
New Cancer Drug Approved for Prostate Cancer Treatment
|
|
| 12:10 ET |
Chemotherapy Drug Taxotere Extends Life of Prostate Cancer Patients
|
|
| 12:05 ET |
Southwest Oncology Group Trial Shows That Taxotere(R) Significantly Improves Survival in Men With Prostate Cancer
|
|
| 12:00 ET |
Two Landmark Studies Show That Taxotere(R) Significantly Improves Survival in Men With Prostate Cancer
|
|
| 11:46 ET |
International Myeloma Foundation Heralds ECOG Announcement
|
|
| 10:22 ET |
Bonefos(R) Increases Survival in Primary Operable Breast Cancer Patients
|
|
| 09:30 ET |
Scientific Data Presented at ASCO Annual Meeting Evaluating ERBITUX(TM) (Cetuximab) in Advanced Non-Small-Cell Lung Cancer (Abstracts 7012 and 7084)
|
|
| 09:15 ET |
Phase III Data Presented at ASCO Demonstrate Saforis(TM) Helps Prevent and Treat the Most Common, Unmanaged Toxicity of Cancer Therapy
|
|
| 09:05 ET |
Human Genome Sciences Reports Results of Phase 1 Clinical Trials of HGS-ETR1 (TRAIL-R1 MAB) in Patients with Advanced Cancers
|
 |
| 09:03 ET |
CEL-SCI Publishes Phase II Clinical Trial Results at ASCO
|
|
| 09:03 ET |
The Addition of Eloxatin(TM) to gemcitabine Significantly Improves the Treatment of Advanced Pancreatic Cancer
|
|
| 09:03 ET |
Vion Presents Clinical Data on CLORETAZINE(TM) (VNP40101M) Phase I Trial of a Weekly Schedule at ASCO(R) Meeting
|
|
| 09:02 ET |
Medarex Announces Positive Data with MDX-010 and Dacarbazine Combination in Metastatic Melanoma Phase II Study
|
|
| 09:01 ET |
Cell Genesys Reports Follow-Up Clinical Data From Phase 2 Trial Of GVAX(R) Prostate Cancer Vaccine
|
|
| 08:33 ET |
Genaera Presents Updated Phase II Lung Cancer Clinical Trial Results at ASCO
|
|
| 08:07 ET |
Immunomedics Reports Advances in Lymphoma and Multiple Myeloma Therapy at the 40th Meeting of American Society of Clinical Oncology
|
|
| 07:31 ET |
Vion Presents Phase I Clinical Data on CLORETAZINE(TM) (VNP40101M) and Ara-C Combination in Leukemia at ASCO(R) Meeting
|
|
| 07:04 ET |
American Pharmaceutical Partners Reports That Weekly Administration of ABRAXANE(TM) is Active in Patients Who Had Failed Treatment for Breast Cancer With TAXOL or Taxotere Therapy
|
|
| 07:01 ET |
Corixa and GlaxoSmithKline Announce Results of Two Studies of BEXXAR(R) Following Chemotherapy as First-Line Treatment of Non-Hodgkin's Lymphoma Presented At ASCO
|
|
| 07:01 ET |
GTx, Inc. Presents Positive Preclinical and Clinical Data for ACAPODENE(TM) at the American Society of Clinical Oncology Meeting
|
|
| 07:00 ET |
GenVec Presents Promising Survival Data for TNFerade(TM) in Phase II Pancreatic Cancer Study
|
|
| 03:00 ET |
MabCampath Continues to Improve Survival For Patients With Chronic Lymphocytic Leukemia (CLL)
|
|
Jun 06, 04
|
| 15:30 ET |
TRISENOX(R) Produces Durable Responses and Transfusion Independence in both Low- and High-Risk Patients with Myelodysplasia
|
|
| 15:14 ET |
Final Results For IRESSA(R) (gefitinib) Tablets Reported From Compassionate Use Program in Non-Small-Cell Lung Cancer Patients
|
|
| 14:30 ET |
Veglin Phase I Trial Shows Potential in Fighting Angiogenesis and Tumor Progression
|
|
| 14:01 ET |
ADVR Presented Results of its AVR118 Phase 1/2 Clinical Program at ASCO
|
|
| 14:01 ET |
Data Show Ethyol(R) Reduces Radiation Therapy-Induced Dry Mouth in Head and Neck Cancer Patients For 24 Months
|
|
| 14:01 ET |
Findings from National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol C-06 Showed that Oral Chemotherapy (UFT plus Leucovorin) for the Adjuvant Treatment of Stage II/III Colorectal Cancer was Equally Effective and Tolerated as Standard Intrav
|
|
| 14:00 ET |
Cell Genesys Reports Interim Data From Phase 2 Clinical Trial of GVAX(R) Leukemia Vaccine
|
|
| 14:00 ET |
Millennium Announces Findings From a Phase I Clinical Trial of MLN2704 in Progressive, Metastatic Hormone-Refractory Prostate Cancer
|
|
| 13:45 ET |
Lapatinib Shows Anti-Tumour Activity in Herceptin(R) - Resistant Breast Cancer Patients
|
|
| 13:05 ET |
Data From Phase 3 Trial of Allos Therapeutics' RSR13 (efaproxiral) Presented at ASCO
|
|
| 12:48 ET |
Analysis From Phase 3 Trial Suggests That Some Non-Small Cell Lung Cancer Patients With Brain Metastases May Benefit From Allos Therapeutics' RSR13 (Efaproxiral)
|
|
| 09:13 ET |
Phase III Data Presented at ASCO Demonstrate Saforis(TM) Helps Prevent and Treat the Most Common, Unmanaged Toxicity of Cancer Therapy
|
|
| 09:01 ET |
VELCADE(R) (Bortezomib) for Injection Shows Promising Activity in Two Phase II Studies of Patients with Previously Untreated Multiple Myeloma
|
|
| 09:00 ET |
17-AAG Phase I and Ib Combination Trial Results Reported at the American Society of Clinical Oncology Meeting
|
|
| 09:00 ET |
Cell Genesys Reports Final Results of Phase 1/2 Trial of CG7870 Oncolytic Virus Therapy for Prostate Cancer
|
|
| 09:00 ET |
Scientific Data Presented at ASCO Annual Meeting Evaluating ERBITUX(TM) (Cetuximab) in Colorectal Cancer (Abstracts 3510, 3513, 3512 and 3531)
|
|
Jun 05, 04
|
| 18:57 ET |
The Susan G. Komen Breast Cancer Foundation Believes Pharmacogenomics Offers Hope for Targeted, Personalized Breast Cancer Treatments
|
|
| 17:15 ET |
Early Clinical Data Evaluating the Combination of Avastin and Tarceva Yield Initial Promising Results in Several Cancers
|
|
| 16:30 ET |
Significant Improvements in Efficacy With Weekly Chemotherapy (Paclitaxel) Compared to Standard 3-Weekly Therapy in Women With Advanced Breast Cancer
|
|
| 15:43 ET |
Early Clinical Data Evaluating the Combination of Avastin and Tarceva Yield Initial Promising Results in Several Cancers
|
|
| 14:00 ET |
ZEVALIN(R) Following Short Duration RITUXAN(R)/Chemotherapy Produces High Complete Remission Rates in First-Line Treatment of Follicular NHL
|
|
| 11:00 ET |
Preliminary Results of a Phase III Study Showed Rituxan Maintenance Therapy Improved Progression-Free Survival in Newly Diagnosed Patients With Indolent Non-Hodgkin's Lymphoma
|
|
| 09:05 ET |
Telik Announces 27% Objective Response Rate in Phase 2 Trial Of Telcyta(TM) in Combination With Docetaxel in Platinum-Resistant Non-Small Cell Lung Cancer
|
|
| 09:05 ET |
Telik Announces 46% Objective Response Rate in Phase 2 Trial of Telcyta(TM) in Combination With Liposomal Doxorubicin in Platinum Refractory or Resistant Ovarian Cancer
|
|
| 09:05 ET |
Telik Announces 56% Objective Response Rate of Telcyta(TM) in Combination With Carboplatin in Phase 2 Study in Platinum Refractory or Resistant Ovarian Cancer
|
|
| 09:01 ET |
Threshold Pharmaceuticals to Present Data on Glufosfamide Trial Results at 2004 ASCO Annual Meeting
|
|
| 09:00 ET |
Coley Pharmaceutical Group's Investigational Drug ProMune(TM) Shows Improved Responses in First-Line Chemotherapy of Advanced Non-Small Cell Lung Cancer
|
|
| 09:00 ET |
Phase III Study of Erbitux(TM) (Cetuximab) and High-Dose Radiation in Locally Advanced Head and Neck Cancer Presented at ASCO (Abstract 5507)
|
|
| 08:45 ET |
Genomic Health, Inc. and Istituto Nazionale Tumori Announce Encouraging Preliminary Clinical Trial Results of Oncotype DX(TM) Assay in Predicting Response to Chemotherapy in Breast Cancer
|
|
Jun 04, 04
|
| 17:43 ET |
Improved Technology Hastens the Release of New Drugs for Cancer and Other Diseases
|
|
| 09:01 ET |
Baxa to Feature the PhaSeal(R) Closed System for Safe Handling of Hazardous Drugs at ASCO Annual Meeting in New Orleans June 5-8
|
|
| 07:00 ET |
Cell Therapeutics, Inc. Hosts Investor Meeting at ASCO
|
|
Jun 03, 04
|
| 13:46 ET |
New Data on Immunomedics' Cancer Therapeutics to Be Presented at 40th Annual Meeting of American Society of Clinical Oncology (ASCO)
|
|
| 09:01 ET |
Medarex Announces Upcoming Presentations at American Society of Clinical Oncology Meeting
|
|
| 08:32 ET |
Coley Pharmaceutical Group Announces ProMune(TM) (CpG 7909) Presentations at ASCO
|
|
Jun 02, 04
|
| 16:20 ET |
ACLARA eTag Technology to be Discussed at ASCO Annual Meeting
|
|
| 08:32 ET |
Alfacell Corporation Welcomes David Sidransky, M.D. to Board of Directors
|
|
| 08:02 ET |
Cytogen Announces New QUADRAMET(TM) Data to be Released at the American Society of Clinical Oncology - ASCO - Meeting
|
|
| 07:32 ET |
Clinical Data on THALOMID(R), REVLIMID(TM), ACTIMID(TM) and ALKERAN(R) in Hematological and Solid Tumor Cancers at The American Society of Clinical Oncology
|
|
Jun 01, 04
|
| 10:03 ET |
New Data on AstraZeneca Oncology Products to be Presented at Annual American Society of Clinical Oncology (ASCO) Meeting
|
|
May 26, 04
|
| 15:08 ET |
Genomic Health, Inc. Announces Preliminary Clinical Trial Results of Oncotype DX(TM) Assay in Predicting Response to Chemotherapy in Breast Cancer to be Presented at the American Society of Clinical Oncology (ASCO) meeting
|
|
| 08:01 ET |
Two Landmark Studies of Taxotere(R) in Prostate Cancer Highlighted in American Society of Clinical Oncology Plenary Session
|
|
May 12, 04
|
| 08:45 ET |
Transgene to Present Data at 2004 ASCO Annual Meeting
|
|
May 06, 04
|
| 16:01 ET |
Medarex Announces 2004 First Quarter Financial Results
|
|
Mar 24, 04
|
| 07:00 ET |
Cell Genesys to Update Results from GVAX(R) Prostate Cancer Vaccine and Other Clinical Trial Programs at 2004 ASCO Annual Meeting
|
|
Mar 19, 04
|
| 09:30 ET |
CEL-SCI Corporation Releases Letter to Shareholders
|
|
Mar 11, 04
|
| 09:01 ET |
CEL-SCI Abstract Selected for Publication in the American Society of Clinical Oncology (ASCO) Proceedings
|
|